Results 81 to 90 of about 47,014 (182)

Clinical Factors Associated With Pneumocystis Pneumonia Despite Its Primary Prophylaxis: When to Stop Prophylaxis?

open access: yesArthritis &Rheumatology, EarlyView.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim   +5 more
wiley   +1 more source

Expert perspective: How, When, and Why to Potentially Stop Anti‐resorptive Drugs in Osteoporosis

open access: yesArthritis &Rheumatology, Accepted Article.
Osteoporosis is a chronic disease and anti‐resorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used anti‐resorptive treatments bisphosphonates and denosumab have short and longer term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G Saag
wiley   +1 more source

Specifications of the ACMG/AMP variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel

open access: yesHuman Mutation, Volume 43, Issue 12, Page 2170-2186, December 2022., 2022
Abstract The standardization of variant curation criteria is essential for accurate interpretation of genetic results and clinical care of patients. The variant curation guidelines developed by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) in 2015 are widely used but are not gene specific.
Kathryn P. Burdon   +14 more
wiley   +1 more source

Time‐dependent effect of prophylactic trimethoprim‐sulfamethoxazole on the incidence of serious infections in ANCA‐associated vasculitis: A target trial emulation study

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives To investigate the effect of prophylactic trimethoprim‐sulfamethoxazole (TMP‐SMX) on the incidence of serious infections in patients with anti‐neutrophil cytoplasmic antibody‐associated vasculitis (AAV). Methods This multicenter cohort study designed to emulate a target trial studied 296 patients with AAV treated with rituximab or ...
Yun Kyu Kim   +7 more
wiley   +1 more source

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease‐modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK‐pot" study)

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess the incidence of major adverse cardiovascular events (MACE) in RA patients treated with JAKi, TNF‐inhibitors (TNFi) or biologic Disease‐Modifying Anti‐Rheumatic Drugs with other modes of action (bDMARD‐OMA) in a multi‐country, real‐world population.
Romain Aymon   +28 more
wiley   +1 more source

Effect of long‐term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies

open access: yesArthritis &Rheumatology, Accepted Article.
Objective This study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials. Methods Patients were randomized to voclosporin or placebo treatment for up to three years; all patients received mycophenolate mofetil and low‐dose ...
Brad H. Rovin   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy